

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EL820015553US Express Mail Label Number	June 21, 2002 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
IMBACH ET AL.

Art Unit: 1624


Examiner: Mark Berch

APPLICATION NO: 09/927,322

FILED: AUGUST 10, 2001

FOR: 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS  
MEDICAMENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231



RECEIVED  
JUL 03 2002

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

  
George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593  
(908) 522-6922

Date: June 21, 2002

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820015553US  
Express Mail Label NumberJune 21, 2002  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF


Art Unit: 1624

IMBACH ET AL.

Examiner: Mark Berch

APPLICATION NO: 09/927,322

FILED: AUGUST 10, 2001

FOR: 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS  
MEDICAMENTSAssistant Commissioner for Patents  
Washington, D.C. 20231FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593  
(908) 522-6922

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

Date: June 21, 2002